Navigation Links
Agendia Joins the Personalized Medicine Coalition (PMC)
Date:9/26/2007

AMSTERDAM, September 26 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of cancer molecular diagnostics, announces that it has joint the US-based Personalized Medicine Coalition (PMC).

"The PMC is playing a key role in shaping the US public policy on personalized medicine. We are very pleased to be a member of a group that will dramatically impact the treatment of patients in the future. After we got both our first IVDMIA product, MammaPrint(R), as well as our logistical sampling and shipping procedure, RNARetain(R)(1), cleared by the FDA we believe it is now time to actively participate in the discussion about the implementation of personalized medicine in the US", said Dr. Bernhard Sixt, CEO of Agendia BV.

Edward Abrahams, Executive Director of the PMC, welcomed the addition of the Netherlands-based personalized medicine company: "We very much look forward to Agendia's involvement in PMC's activities, in particular its participation in our efforts to shape an appropriate regulatory pathway for personalized medicine products."

About PMC

The Personalized medicine coalition was publicly launched in November 2004 by more than a dozen leading pharmaceutical, biotechnology, diagnostics and information technology companies, along with major academic centres and governmental agencies. An independent, non-profit group dedicated to advancing the understanding and adoption of personalized medicine concepts and products for the benefit of patients, it represents over 100 members. The Coalition seeks to promote discussion and understanding that will lead to the development of sound public policy on matters that affect the realization of personalized medicine.

About Agendia

Agendia, located in Amsterdam, the Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commercialization of diagnostic tests using tumor gene expression profiling. Agendia was the first company to commercialize a prognostic test - MammaPrint(R) - that predicts the risk of breast cancer recurrence. Its second microarray product, CupPrint(R)(2), is a diagnostic test to identify the origin of a metastasis in a cancer type called "Cancer of Unknown Primary". Agendia recently also presented its new colon cancer prognosis profile, ColoPrint(R), which is currently undergoing further validation.

Agendia maintains close ties with several leading academic centers to develop state of the art diagnostic tests for cancer. Agendia also offers its expertise to pharma companies focusing on development of highly effective personalized drugs in the area of oncology.

(1) RNARetain(R) is a trademark of Asuragen Inc.

(2) CupPrint(R) is based on a license to the TUO database of AviaraDx Inc.


'/>"/>
SOURCE Agendia BV
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Chemical-petroleum executive joins Virent Energy board
2. Schneider National exec joins TrafficCast board
3. Doyle joins governors in support of stem cell bill
4. Genomics researcher Hood joins NimbleGen board
5. Fergus joins Baird Venture Partners, Caden Bio
6. Meier joins Broadlook Technologies as COO
7. Prodesse joins forces with Invitrogen
8. Wisconsin joins price-fixing suit vs. D-RAM makers
9. Napier joins board of Third Wave Technologies
10. Schmidt rejoins Renaissance Learning
11. Tommy Thompson joins drug company as advisor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... ... , ... In a list published by the Boston Business Journal, iLab ... a small percentage of the state's 615,000+ small businesses. The list examined companies based ... from 2012 to 2015. , As this award comes on the heels ...
(Date:5/3/2016)... Westminster, CO (PRWEB) , ... May 03, 2016 ... ... analysis , announced the addition of Dr. Nancy Gillett to its Board of ... last position, she served as Corporate Executive Vice President and Chief Scientific Officer. ...
(Date:5/3/2016)... ... May 03, 2016 , ... ... the sensor and data driven conferences, will take place on June 7-8, 2016, at the New ... Vidya Raman-Tangella on incorporating technology -- including AR/VR, machine learning, apps, robotics and AI ...
(Date:5/3/2016)... May 3, 2016  Dr. Thomas P. McHugh ... The Woodlands, Texas , now offers ... of treated fat cells in just 25-minutes, leaving a ... 90 percent of Americans report feeling bothered by excess ... reduction procedures are a growing industry. This innovative new ...
Breaking Biology Technology:
(Date:4/26/2016)... India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a product ... and Onegini today announced a partnership to integrate ... solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... to provide their customers enhanced security to access ...
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):